

DMD #76612

**Identification of flavin-containing monooxygenase 5 (FMO5) as a regulator of glucose homeostasis and a potential sensor of gut bacteria**

Flora Scott, Sandra G. Gonzalez Malagon, Brett A. O'Brien, Diede Fennema, Sunil

Veeravalli, Clarissa R. Coveney, Ian R. Phillips and Elizabeth A. Shephard

Institute of Structural and Molecular Biology, University College London, London, UK (FS, SGGM, BA O'B, DF, SV, CRC, IRP, ES)

School of Biological and Chemical Sciences, Queen Mary University of London, London, UK (IRP)

DMD #76612

**Running title:** FMO5 regulates glucose homeostasis and senses gut bacteria

**Corresponding author:** Elizabeth A. Shephard, Institute of Structural and Molecular Biology, University College London, London WC1E 6BT, UK

Phone: +44 (0) 2076792321

Email: e.shephard@ucl.ac.uk

Number of text pages: 29

Number of tables: 0

Number of figures: 5

Number of References: 55

Number of words in Abstract: 249

Number of words in Introduction: 592

Number of words in Discussion: 1,221

**Abbreviations:** AUC, area under the curve; C3, complement component 3; FMO, flavin-containing monooxygenase; GTT, glucose tolerance test; iAUC, inverse area under the curve; IST, insulin sensitivity test; PXR, pregnane X receptor; RELM  $\beta$ , resistin-like molecule  $\beta$ ; TNF $\alpha$ , tumor necrosis factor  $\alpha$ ; WAT, white adipose tissue; WT, wild-type.

DMD #76612

## Abstract

We have previously identified flavin-containing monooxygenase 5 (FMO5) as a regulator of metabolic ageing. The aim of the present study was to investigate the role of FMO5 in glucose homeostasis and the impact of diet and gut flora on the phenotype of mice in which the *Fmo5* gene has been disrupted (*Fmo5*<sup>-/-</sup> mice). In comparison with wild-type (WT) counterparts, *Fmo5*<sup>-/-</sup> mice are resistant to age-related changes in glucose homeostasis and maintain the higher glucose tolerance and insulin sensitivity characteristic of young animals. When fed a high-fat diet they are protected against weight gain and reduction of insulin sensitivity. The phenotype of *Fmo5*<sup>-/-</sup> mice is independent of diet and the gut microbiome and is determined solely by the host genotype. *Fmo5*<sup>-/-</sup> mice have similar metabolic characteristics to germ-free mice indicating that FMO5 plays a role in sensing or responding to gut bacteria. In WT mice, FMO5 is present in the mucosal epithelium of the gastrointestinal tract where it is induced in response to a high-fat diet. In comparison with WT mice, *Fmo5*<sup>-/-</sup> mice have fewer colonic goblet cells and they differ in the production of the colonic hormone resistin-like molecule  $\beta$ . *Fmo5*<sup>-/-</sup> mice have lower concentrations of tumor necrosis factor  $\alpha$  in plasma and of complement component 3 in epididymal white adipose tissue, indicative of improved inflammatory tone. Our results implicate FMO5 as a regulator of body weight and of glucose disposal and insulin sensitivity and, thus, identify FMO5 as a potential novel therapeutic target for obesity and insulin resistance.

## INTRODUCTION

Flavin-containing monooxygenases (FMOs) (EC 1.14.13.8) of mammals play an important role in the NADPH-dependent oxidative metabolism of a wide array of foreign chemicals (Krueger and Williams, 2005). FMOs 1, 2 and 3 catalyze the *N*- and *S*-oxygenation of a structurally diverse range of xenobiotics, including therapeutic drugs, dietary components and environmental pollutants (Krueger and Williams, 2005; Phillips *et al.*, 2007). FMO5 differs markedly from FMOs 1, 2 and 3 with respect to its substrate specificities (Phillips and Shephard, 2017). Although FMO5 catalyzes the *N*-oxygenation of short-chain aliphatic primary amines such as *N*-octylamine (Overby *et al.*, 1995) and the *S*-oxygenation of *S*-methyl-esonarimod, an active metabolite of the anti-rheumatic esonarimod (Ohmi *et al.*, 2003; Zhang *et al.*, 2007), it is apparently more efficient in catalyzing the oxygenation of a variety of carbonyl compounds, via a Baeyer-Villiger process (Fiorentini *et al.*, 2016), including the anti-cancer drug E7016 (Lai *et al.*, 2011) and the antibacterial agent MRX-I (Meng *et al.*, 2015). FMOs 1, 2 and 3 (Siddens *et al.*, 2014) and FMO5 (Fiorentini *et al.*, 2016) can act also as NADPH oxidases, producing hydrogen peroxide.

In human and mouse the tissue-specific pattern of expression of FMO5 is similar, unlike those of FMO1 or FMO3, which show distinct differences in hepatic expression between these species (Dolphin *et al.*, 1991; 1996; Janmohamed *et al.*, 2004). FMO5 is most highly expressed in liver (Overby *et al.*, 1997; Zhang and Cashman, 2006) and skin (Janmohamed *et al.*, 2001) and moderately expressed in other tissues, including the small intestine (Hernandez *et al.*, 2004; Zhang and Cashman, 2006; Fu *et al.*, 2016).

Very few single-nucleotide polymorphisms (SNPs) have been identified in the coding region of the human *FMO5* gene and none has been shown to influence enzyme activity (Furnes *et*

## DMD #76612

*al.*, 2003; Phillips *et al.*, 2007). *FMO5* gene expression, however, is increased by several chemicals, including the hormones progesterone (Miller *et al.*, 1997) and testosterone (Houseman *et al.*, 2015) and the pregnane X receptor (PXR) ligands hyperforin (Krusekopf and Roots, 2005) and rifampicin (Rae *et al.*, 2001; Houseman *et al.*, 2015). Activation of PXR has been proposed as a factor contributing to type 2 diabetes (Hukkanen *et al.*, 2014). Interindividual variation in the expression of *FMO5* in human liver has been reported (Overby *et al.*, 1997). Given the inducible nature of the gene, such variation is likely due to physiological or environmental factors.

Through the use of knockout mouse lines we have shown that, in addition to their involvement in the metabolism of foreign chemicals, two members of the FMO family, *FMO1* and *FMO5*, play roles in endogenous metabolism. *FMO1* has been identified as a regulator of energy homeostasis (Veeravalli *et al.*, 2014) and *FMO5* as a promoter of metabolic ageing (Gonzalez Malagon *et al.*, 2015). *Fmo5*<sup>-/-</sup> mice exhibit an age-related lean phenotype: in comparison with their wild-type (WT) counterparts, as they age they gain less weight, store less fat in white adipose tissue (WAT), have lower plasma concentrations of glucose and cholesterol and enhanced whole-body energy expenditure, with no increase in physical activity (Gonzalez Malagon *et al.*, 2015).

The present study extends our characterization of the metabolic phenotype of *Fmo5*<sup>-/-</sup> mice, focusing on the potential role of *FMO5* in regulating glucose homeostasis and the effects on the phenotype of diet and gut flora. We show that *Fmo5*<sup>-/-</sup> mice are resistant to age-related changes in glucose homeostasis and are protected against weight gain and reduction of insulin sensitivity in response to a high-fat diet. The phenotype is independent of the gut microbiome and our results implicate *FMO5* as an intestinal microbial sensor.

DMD #76612

## MATERIALS AND METHODS

### Animal maintenance

Homozygous knockout mice (*Fmo5*<sup>-/-</sup>) used in this study were generated on the C57BL/6J background and back-crossed for eight generations, as described previously (Gonzalez Malagon *et al.*, 2015). WT C57BL/6J mice were used as controls. Both mouse lines were bred and housed in the same room at UCL. All experiments were done on male animals. Mice were given free access to water and fed *ad libitum* with a standard chow diet (Teklad Global 18% Protein Rodent Diet, Harlan Laboratories, Inc., Madison, WI) or, where specified, a high-fat diet (AIN-93M w/ 35 % Kcal Fat, TestDiet, St. Louis, MO). Tissue and blood samples were collected between 9:30 a.m. and 12:00 noon, unless stated otherwise. Animal procedures were carried out in accordance with the UK Animal Scientific Procedures Act and with local ethics committee approval (AWERB) and appropriate Home Office Licenses.

### Plasma analyses

Blood was collected and plasma isolated as described (Hough *et al.*, 2002). Mice fed a high-fat diet and their standard chow-fed age-matched controls were starved overnight before blood withdrawal. The concentration of glucose in plasma was determined via an autoanalyser at the MRC Mammalian Genomics Unit, Harwell, Oxfordshire, UK and in whole blood through the use of a CONTOUR® XT Meter (Bayer AG, Leverkusen, Germany). Commercially available ELISA kits were used to determine plasma concentrations of insulin (Rat/Mouse Insulin ELISA, Millipore, Watford, Herts, UK) and TNF $\alpha$  (TNF $\alpha$  Mouse EIA kit, Enzo, Exeter, Devon, UK). Plasma lipopolysaccharide was measured by Lonza Endotoxin Service Europe, Verviers, Belgium, using the Limulus

DMD #76612

Amebocyte Lysate assay.

### **Intraperitoneal glucose tolerance and insulin sensitivity tests**

Glucose tolerance tests (GTT) and insulin sensitivity tests (IST) were performed as described (Heikkinen *et al.*, 2007) on animals that had been fasted either overnight (15 h) (GTT) or for 6 h (IST). Fasting blood glucose was measured through the use of a CONTOUR® XT Meter (Bayer AG). Animals were then injected intraperitoneally with glucose (2 g/kg bodyweight) (GTT) or insulin (0.25 IU/kg bodyweight) (ITT). Blood glucose was then measured 15, 30, 60, 90 and 120 (GTT) or 15, 30, 45, 60, 75 and 90 (IST) min post injection. For statistical analysis, area under the curve (AUC) or inverse area under the curve (iAUC) was calculated as appropriate (Heikkinen *et al.*, 2007).

### **Intestinal microbiota analysis**

DNA was isolated from frozen fecal pellets through the use of the Isolate Faecal DNA Kit (Bioline, London, UK) according to the manufacturer's recommendations, except for an additional 30 min of shaking after addition of lysis buffer. Bacterial 16S rRNA gene sequences were amplified using the universal 16S rRNA primer pair, forward 8FE (5'-AGAGTTTGATCCTGGCTCAG-3') (Salzman *et al.*, 2002) and reverse 1387r (5'-GGGCGGTGTGTACAAGGC-3') (Marchesi *et al.*, 1998), and Biotaq™ DNA polymerase (Bioline). Approximately 16 ng of fecal DNA and 5 pmoles each of forward and reverse primers were used per 25-μL reaction volume. PCR conditions were 5 min at 95 °C, followed by 30 cycles of 95 °C for 1 min, 51 °C for 1 min and 72 °C for 1 min, and a final elongation at 72 °C for 5 min. Amplification products were ligated into pGEM-T (Promega,

DMD #76612

Southampton, Hants, UK). Electrocompetent *Escherichia coli* JM109 cells were transformed with ligation products. Recombinant colonies were individually stabbed into agar-containing 96-well plates. Plasmid isolation and DNA sequencing were performed by LGC Genomics GmbH (Berlin, Germany). Sequences were identified by comparison with known 16S rRNA gene sequences in the Ribosomal Database Project (<http://rdp.cme.msu.edu>).

### **Antibiotic treatment**

At 30 weeks of age, animals were given ampicillin ( $1 \text{ g.L}^{-1}$ ) and neomycin ( $0.5 \text{ g.L}^{-1}$ ) in their drinking water for 14 days. Antibiotic-containing water was replenished twice weekly and animals were given free access to the standard chow diet.

### **Histology and immunohistochemistry**

Sections of digestive tract were fixed in 10 % (v/v) neutral buffered formalin (Leica Biosystems, Milton Keynes, Bucks, UK). Tissue samples were embedded in paraffin and sections stained with hemotoxylin and eosin at the MRC Mary Lyon Centre (Harwell, Oxon, UK). Immunohistochemistry of tissue sections was carried out by UCL Advanced Diagnostics (London, UK). FMO5 was detected using a polyclonal antibody (16864-1-AP, ProteinTech™, Manchester, UK), diluted 1:100 (Antibody Diluent Background Reducing, Dako, Ely, Cambs, UK). RELMβ was detected using a polyclonal antibody (ab11429, Abcam®, Cambridge, Cambs, UK), diluted 1:400 (Bond™ Primary Antibody Diluent, Leica Biosystems). Cell nuclei were counterstained with hematoxylin. Colonic sections were stained with Alcian Blue and counterstained with Neutral Red (UCL Advanced Diagnostics). Goblet cells were quantified as described (Mello *et al.*, 2012).



## Western blot analysis

Fecal samples, colon contents, liver and epididymal adipose tissues were homogenized using a Tissue Lyser II (Qiagen, Crawley, W Sussex, UK) in ice-cold Triton lysis buffer (1% Triton X-100, 140 mM NaCl, 10 mM Tris-HCl, pH8, 1 mM EDTA, 1 mM PMSF) containing Halt™ Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific, Loughborough, Leics, UK). To ensure sufficient homogenization samples were agitated for an additional 15 min (liver and adipose tissue) or 40 min (fecal and colon samples) at 4 °C. Homogenates were centrifuged at 12,000 g for 20 min at 4 °C. For detection of FMO5 in fecal samples, homogenates were concentrated by precipitation with trichloroacetic acid, then resuspended in 200 mM Tris-HCl (pH8.5), 10 mM EDTA, 6 M urea, 0.5% (w/v) SDS. Samples were adjusted to final concentrations of 50 mM Tris-HCl, pH 6.8, 10 % (v/v) glycerol, 2 % (w/v) SDS, 0.25 % (w/v) bromophenol blue, 100 mM DTT. Samples were then heated at 95 °C for 5 min and analysed by SDS-PAGE and western blotting. Proteins were detected by the use of antibodies against FMO5 (16864-1-AP, ProteinTech™), beta-actin (Proteintech 66009-1-Ig), RELMβ (ab11429, Abcam®), complement component 3 (C3) (204869, Millipore) and enolase (sc-15343, Santa Cruz Biotechnology®, Heidelberg, Germany). For primary antibodies against FMO5, RELMβ and enolase a secondary anti-rabbit antibody conjugated to horseradish peroxidase (HRP) (Donkey Anti- Rabbit IgG H+L (HRP), Abcam®) was used. For beta-actin, goat anti-mouse secondary antibody IR 680 [Alexa Flour A21057] (Life Technologies Ltd, Paisley, UK) was used. For C3, a secondary anti-goat antibody conjugated to HRP (Rabbit Anti-Goat IgG-HRP conjugate, Alpha Diagnostic, San Antonio, TX) was used. Blots were incubated with secondary antibodies for 1 h at room temperature before enhanced chemiluminescence detection, as described previously (Gonzalez Malagon *et al.*,

DMD #76612

2015), using an Odyssey® Fc Dual-Mode Imaging System (LiCor®, Cambridge, Cambs, UK). For fecal and colon contents, to control for protein loading, the amount of protein loaded onto each well was assessed by scanning densitometry of the whole length of each lane using GelQuant.Net software, version 1.8.2 (biochemlabsolutions.com). Individual protein signals on western blots were quantified using LI-COR Image Studio Lite, version 3.1.4.

### Statistical analysis

Data are expressed as mean  $\pm$  standard error of the mean (SEM). Statistical significance was determined using an unpaired two-tailed t-test and GraphPad Prism (V. 6.0e) (GraphPad Software, Inc., La Jolla, CA). The following symbols were used throughout all figures and text to indicate the significance value:  $*P < 0.05$ ,  $**P < 0.01$ ,  $***P < 0.001$ ,  $****P < 0.0001$ .

## RESULTS

### *Fmo5*<sup>-/-</sup> mice are resistant to age-related changes in glucose homeostasis and insulin sensitivity

The plasma concentration of glucose in 6-week-old *Fmo5*<sup>-/-</sup> mice was similar to that in WT mice (Fig. 1A). From 6 to 15 weeks of age it decreased, to the same extent, in both *Fmo5*<sup>-/-</sup> and WT mice. A similar decrease has been reported for mice as they age from immature to young adult (Bailey and Flatt, 1982). From 15 weeks of age, the plasma glucose of WT, but not of *Fmo5*<sup>-/-</sup> mice, increased and by 30 weeks was  $10.85 \pm 0.20$  mmol/l ( $n = 18$ ) in WT and  $9.21 \pm 0.35$  mmol/l ( $n = 17$ ) in *Fmo5*<sup>-/-</sup> mice ( $P < 0.001$ , *Fmo5*<sup>-/-</sup> vs WT) (Fig. 1A). The results confirm and extend our previous findings on 10- and 30-week-old mice (Gonzalez Malagon *et al.*, 2015) and indicate that the lower plasma concentration of glucose in *Fmo5*<sup>-/-</sup>

## DMD #76612

compared with WT mice at 30 weeks of age is the result of a lack of increase, rather than a decrease, in plasma glucose of *Fmo5*<sup>-/-</sup> mice as they age from 15 to 30 weeks. At 15 and 30 weeks of age both WT and *Fmo5*<sup>-/-</sup> mice responded to a 12-h overnight withdrawal of food by decreasing their plasma glucose by ~ 25% (data not shown).

At 10 weeks of age, the plasma concentration of insulin in *Fmo5*<sup>-/-</sup> and WT mice was the same (Fig. 1B). As mice aged, the plasma insulin of WT mice increased, but that of *Fmo5*<sup>-/-</sup> animals remained the same and by 30 weeks of age the plasma insulin concentration of WT mice ( $1.92 \pm 0.13$  ng/ml,  $n = 3$ ) was 3-fold more than that of *Fmo5*<sup>-/-</sup> mice ( $0.63 \pm 0.08$  ng/ml,  $n = 3$ ) ( $P < 0.01$ ). Therefore, at 15 and 30 weeks of age, although the plasma concentration of glucose of *Fmo5*<sup>-/-</sup> mice was the same or lower than that of WT mice (Fig. 1A), they required less insulin to maintain the concentration.

Glucose tolerance of *Fmo5*<sup>-/-</sup> and WT mice was the same at 15 weeks of age (Fig. 1C). By 30 weeks, *Fmo5*<sup>-/-</sup> mice, despite having lower plasma insulin than WT mice (Fig. 1B), had significantly higher glucose tolerance (Fig. 1D). The similarity in peak glucose suggests no difference in pancreatic  $\beta$ -cell function between *Fmo5*<sup>-/-</sup> and WT mice, whereas the larger AUC of WT mice is indicative of greater whole-body insulin resistance. As early as 10 weeks of age *Fmo5*<sup>-/-</sup> mice responded to insulin more quickly and to a greater extent than did WT mice (Fig. 1E), indicating that the former had greater basal insulin sensitivity. Our results demonstrate that *Fmo5*<sup>-/-</sup> mice are resistant to the age-related changes in glucose homeostasis and insulin sensitivity exhibited by their WT counterparts.

***Fmo5*<sup>-/-</sup> mice are resistant to weight gain and reduction of insulin sensitivity in response to a high-fat diet**

## DMD #76612

When fed a high-fat diet for a period of six weeks, 33-week-old WT mice increased in weight from  $37.6 \pm 0.7$  g to  $46.2 \pm 0.9$  ( $n = 7$ ), a gain of 23% (Fig. 2A). In contrast, *Fmo5*<sup>-/-</sup> mice gained no weight on the high-fat diet and by 39 weeks of age weighed  $33.8 \pm 1.0$  g ( $n = 6$ ), 27% less than WT mice (Fig. 2A). When fed a standard chow diet over the same period neither WT nor *Fmo5*<sup>-/-</sup> mice of this age increased weight significantly (data not shown). On a standard chow diet *Fmo5*<sup>-/-</sup> mice eat slightly more than WT mice (Gonzalez Malagon *et al.*, 2015). In the case of the high-fat diet, owing to the consistency of the food pellets, which caused them to crumble when eaten, it was not possible to accurately measure food intake. However, the food hoppers of *Fmo5*<sup>-/-</sup> mice had to be replenished more frequently than those of WT mice, suggesting that, as is the case for the standard chow diet, when fed a high-fat diet *Fmo5*<sup>-/-</sup> mice do not eat less than WT mice. Our results demonstrate that, in contrast to WT mice, *Fmo5*<sup>-/-</sup> mice are resistant to high-fat-diet-induced weight gain and that this is unlikely to be a consequence of a reduced intake of food.

In response to a 12-h overnight withdrawal of food, the plasma concentration of glucose in *Fmo5*<sup>-/-</sup> mice fed a high-fat diet was reduced to  $6.98 \pm 0.78$  mmol/l ( $n = 6$ ), which was similar to the concentration in fasted *Fmo5*<sup>-/-</sup> mice on a standard chow diet ( $7.28 \pm 0.20$  mmol/l,  $n = 23$ ). However, WT mice responded less well to a 12-h fast when on a high-fat diet than when on a standard chow diet, reducing plasma glucose to  $9.61 \pm 0.53$  mmol/l ( $n = 7$ ) and  $7.97 \pm 0.27$  mmol/l ( $n = 20$ ), respectively ( $P < 0.05$ ).

The plasma concentration of insulin of WT mice fed a high-fat diet was 10-fold higher than that of WT mice fed a standard chow diet (Fig. 2B). In contrast, in *Fmo5*<sup>-/-</sup> mice the high-fat diet had a much smaller effect on plasma insulin, which was increased to a concentration similar to that of WT mice on a standard chow diet (Fig. 2B). The high-fat diet significantly

DMD #76612

reduced the glucose tolerance of WT mice, but had no effect on that of *Fmo5*<sup>-/-</sup> mice (Fig. 2C). Our results demonstrate that, in comparison with WT mice, *Fmo5*<sup>-/-</sup> mice are resistant to changes in glucose homeostasis as a consequence of a high-fat diet. Our finding that disruption of the *Fmo5* gene renders mice resistant to weight gain and reduction of insulin sensitivity in response to a high-fat diet, suggests that FMO5 is involved in mediating such dietary-induced physiological effects.

### **FMO5 is induced in the intestine in response to a high-fat diet**

The amount of FMO5 present in fecal samples from WT mice was 6-fold more from animals fed a high-fat diet than from those fed a standard chow diet (Fig. 2D), suggesting that intestinal expression of the protein was increased in response to a high-fat diet. However, this was not the case in liver (Fig. 2E), indicating that the high-fat-diet-induced expression of FMO5 was tissue-specific.

### **The phenotype of *Fmo5*<sup>-/-</sup> mice is independent of the gut microbiota**

Five intestinal bacterial phyla were identified in WT and *Fmo5*<sup>-/-</sup> mice fed a standard chow diet: *Actinobacteria*, *Proteobacteria*, *Deferribacteres*, *Firmicutes* and *Bacteroidetes*, of which the *Firmicutes* and *Bacteroidetes* were the most abundant (Fig. 3A). This is in agreement with previous studies of WT mice (Ley *et al.*, 2005). At 7 weeks of age, the *Bacteroidetes* dominated and the gut microbial community ratio of *Bacteroidetes* to *Firmicutes* was the same (4:1) in WT and *Fmo5*<sup>-/-</sup> mice (Fig. 3A). As WT mice aged, the relative abundance of *Bacteroidetes* decreased and that of *Firmicutes* increased, so that by 15 weeks of age the ratio of the phyla had decreased to ~1 (Fig. 3A). A similar, but slower,

## DMD #76612

change in the composition of gut flora occurred in the *Fmo5*<sup>-/-</sup> mice, with the *Bacteroidetes* to *Firmicutes* ratio decreasing to ~3 at 15 weeks and ~1.7 at 30 weeks of age (Fig. 3A). The relative abundance of *Actinobacteria*, *Proteobacteria* and *Deferribacteres* was similar in WT and *Fmo5*<sup>-/-</sup> mice and did not change with age (Fig. 3A).

Although the ratio of *Bacteroidetes* to *Firmicutes* phyla was the same in 7-week-old WT and *Fmo5*<sup>-/-</sup> mice, the abundance of several bacterial families differed (Fig. 3B). For instance, *Porphyromonadaceae* were more prevalent in WT mice and *Prevotellaceae* and *Lachnospiraceae* in *Fmo5*<sup>-/-</sup> animals. By 30 weeks of age, the *Erysipelotrichaceae* family, which was not detected in 7-week-old mice, was twice as abundant in WT as in *Fmo5*<sup>-/-</sup> animals. It is this family that contributed most to the difference in the ratio of *Bacteroidetes* to *Firmicutes* between 30-week-old WT and *Fmo5*<sup>-/-</sup> mice (Fig. 3B).

Six weeks on a high-fat diet had little effect on the relative abundance of *Bacteroidetes* and *Firmicutes* in WT mice, decreasing the ratio of the phyla from 1.0 to 0.9, but had a marked effect in *Fmo5*<sup>-/-</sup> mice, decreasing the ratio from ~1.7 to ~0.4 (Fig. 3A). A lower ratio of *Bacteroidetes* to *Firmicutes* has been associated with an obesogenic state (Ley *et al.*, 2005; Turnbaugh *et al.*, 2009).

The relative abundance of several bacterial families changed in response to a high-fat diet (Fig. 3B). In the *Bacteroidetes* phylum, *Rikenellaceae*, reported to increase in response to high-fat feeding (Daniel *et al.*, 2014), increased in WT but not in *Fmo5*<sup>-/-</sup> mice, whereas *Porphyromonadaceae* decreased, but to a much greater extent (from 33 to 4%) in *Fmo5*<sup>-/-</sup> than in WT mice. Within the *Firmicutes* phylum, the relative abundance of *Lachnospiraceae* increased in *Fmo5*<sup>-/-</sup> but not in WT mice. The most striking change was the almost 3-fold increase in *Erysipelotrichaceae* in *Fmo5*<sup>-/-</sup> mice. On a high-fat diet this family was the most abundant, comprising about a third of the total gut microbiota in both WT and *Fmo5*<sup>-/-</sup> mice.

DMD #76612

*Erysipelotrichaceae* have been reported to increase with diet-induced obesity (Kaakoush, 2015). The marked increase in the abundance of this family in *Fmo5*<sup>-/-</sup> mice fed a high-fat diet was not, however, accompanied by an increase in weight (Fig. 2A). The results indicate that in the *Fmo5*<sup>-/-</sup> mice the composition of gut microbiota changes in response to diet independently of an obese phenotype and that the phenotype of *Fmo5*<sup>-/-</sup> mice is not influenced by diet or gut flora.

Treatment with antibiotics for two weeks had a marked effect on WT mice, reducing the plasma concentration of glucose (Fig. 3C) and of insulin (Fig. 3D), but had no significant effect on *Fmo5*<sup>-/-</sup> mice (Fig. 3C and D). Antibiotic treatment also significantly improved glucose tolerance of WT mice (Fig. 3E). In the case of *Fmo5*<sup>-/-</sup> mice, although at initial time points in the GTT glucose concentrations were lower in antibiotic-treated mice, the AUC was not significantly different (Fig. 3E), indicating that antibiotic treatment did not significantly affect glucose tolerance of the *Fmo5*<sup>-/-</sup> mice. Plasma glucose, plasma insulin and glucose tolerance of antibiotic-treated WT mice were similar to those of non-antibiotic-treated *Fmo5*<sup>-/-</sup> mice (Fig. 3). Therefore, these metabolic parameters were profoundly influenced by gut flora in WT mice, but not in *Fmo5*<sup>-/-</sup> mice, indicating that the phenotype of *Fmo5*<sup>-/-</sup> mice is independent of the gut microbiota and is determined solely by host genotype.

### **FMO5 is expressed throughout the murine digestive tract**

To determine whether FMO5 is expressed in the gut, sections of the digestive tract of WT mice were analysed by immunohistochemistry (Fig. 4). Sections from the gut of *Fmo5*<sup>-/-</sup> mice were used as a negative control. The results revealed that FMO5 was present in the stomach, duodenum, jejunum, ileum (Fig. 4A) and colon (Fig. 4B). In each of these tissues, FMO5 was localized to the columnar epithelium of the mucosa, at the luminal surface. In the stomach, a

## DMD #76612

signal associated with the lamina propria, at the base of the mucosa, was also observed in sections from *Fmo5*<sup>-/-</sup> mice, indicating that it was due to non-specific binding of antibody. Analysis of sections of small intestine (Fig. 4A) and colon (Fig. 4B) of *Fmo5*<sup>-/-</sup> mice resulted in no signal, indicating that signals obtained from WT mice were specific for FMO5. Analysis of intestinal ‘Swiss rolls’ confirmed that FMO5 was expressed throughout the length of both the small intestine and colon of WT mice (data not shown).

In both small (Fig. 4A) and large intestine (Fig. 4B) FMO5 was present throughout the columnar epithelium, including within goblet cells, which are distinguished from other epithelial cells by the presence of a visible secretory granule. FMO5 was not present in the secretory granule itself, but was concentrated in the cytoplasm at the periphery of granules (Fig. 4A and B). In colon, the abundance of FMO5 increased from the base to the luminal opening of crypts (Fig. 4B), in parallel with the maturation of secretory granules.

Staining of transverse sections of stomach, small intestine and colon with hematoxylin and eosin showed no difference between WT and *Fmo5*<sup>-/-</sup> mice in the mucosal thickness or structure of these tissues (data not shown). Thus, although FMO5 was expressed throughout the mucosal epithelium of the murine gastrointestinal tract, in *Fmo5*<sup>-/-</sup> mice its absence did not affect gross morphology of the gut.

### ***Fmo5*<sup>-/-</sup> mice have fewer colonic goblet cells**

Although there was no difference in colonic crypt length between WT ( $151.7 \pm 3.6 \mu\text{m}$ ,  $n=57$ ) and *Fmo5*<sup>-/-</sup> ( $162.1 \pm 5.0 \mu\text{m}$ ,  $n=54$ ) mice, the number of goblet cells per crypt was



significantly lower in *Fmo5*<sup>-/-</sup> ( $15.4 \pm 0.7$ ,  $n = 54$ ) than in WT ( $18.5 \pm 0.8$ ,  $n = 57$ ) mice ( $P < 0.01$ ) (Fig. 4B). Because *Fmo5*<sup>-/-</sup> mice have fewer goblet cells we examined whether this difference influenced the expression of RELM $\beta$ , a hormonally active protein present in goblet cell secretory granules and whose expression is confined to the colon (He *et al.*, 2003). In WT mice RELM $\beta$  was localized to the crypts of the colonic mucosa, where it was concentrated in the secretory granules of goblet cells (Fig. 4C). As was the case for FMO5 (Fig. 4B), a gradient of expression of RELM $\beta$ , increasing from the base of the crypt to the luminal opening, was observed, in agreement with a previous report (He *et al.*, 2003). A similar pattern of RELM $\beta$  expression was observed in the colon of *Fmo5*<sup>-/-</sup> mice (Fig. 4C), indicating that disruption of the *Fmo5* gene had no effect on the localization of RELM $\beta$ .

Analysis of proteins extracted from the luminal contents of the colon (Fig. 4C) identified an ~17 kDa dimeric form of RELM $\beta$  (He *et al.*, 2003) in both WT and *Fmo5*<sup>-/-</sup> mice. However, in WT mice an additional band, migrating at ~8 kDa, corresponding to the monomeric form of RELM $\beta$  (He *et al.*, 2003), was detected. Our results indicate that although *Fmo5*<sup>-/-</sup> mice have fewer colonic goblet cells, disruption of the *Fmo5* gene does not affect expression of RELM $\beta$ , but may affect production of the monomeric form of the protein in the colon. The expression of RELM $\beta$  was markedly reduced by antibiotic treatment (data not shown), as previously reported (Hildebrandt *et al.*, 2009).

### ***Fmo5*<sup>-/-</sup> mice have lower amounts of inflammatory markers**

In view of the potential effect of *Fmo5* on production of the monomeric form of RELM $\beta$  we measured markers of inflammation because, in addition to acting as a mucosecretagogue, RELM $\beta$  is also regarded as an inflammatory mediator (Hogan *et al.*, 2006; McVay *et al.*,

DMD #76612

2006; Krimi *et al.*, 2008). The plasma concentration of the inflammatory cytokine TNF $\alpha$  was ~70% lower in *Fmo5*<sup>-/-</sup> than in WT mice (Fig. 5A). Antibiotic treatment decreased the plasma concentration of TNF $\alpha$  in WT mice to a level similar to that in untreated *Fmo5*<sup>-/-</sup> mice, but had no effect on plasma TNF $\alpha$  in *Fmo5*<sup>-/-</sup> mice (Fig. 5A). As was the case with plasma TNF $\alpha$ , the amount of C3, a visceral adipose inflammatory marker (Hertle *et al.*, 2014), was lower in epididymal adipose tissue of *Fmo5*<sup>-/-</sup> than of WT mice (Fig. 5B). The plasma concentration of lipopolysaccharide in *Fmo5*<sup>-/-</sup> mice ( $3.34 \pm 0.23$  EU/mL,  $n = 3$ ) was the same as that in WT mice ( $3.11 \pm 0.06$  EU/mL,  $n = 3$ ), indicating that disruption of the *Fmo5* gene resulted in no change in intestinal barrier integrity.

## Discussion

As WT C57BL/6J mice aged they exhibited increased plasma concentrations of glucose and insulin and reduced glucose tolerance and insulin sensitivity. In contrast, mice in which the *Fmo5* gene had been disrupted, *Fmo5*<sup>-/-</sup> mice, were resistant to these changes in glucose homeostasis and maintained the higher glucose tolerance and insulin sensitivity characteristic of young animals. In response to a high-fat diet, WT mice increased weight, became hyperinsulinemic and displayed markedly reduced glucose tolerance, indicative of increased whole-body insulin resistance. Again, *Fmo5*<sup>-/-</sup> mice were resistant to these changes indicating that their metabolic phenotype is independent of diet. Our results demonstrate that disruption of the *Fmo5* gene protects mice against diet-induced obesity and the potentially deleterious effects on glucose homeostasis of both age and consumption of high levels of fat and indicate that FMO5 plays a role in the regulation of body weight and of glucose disposal and insulin sensitivity.

## DMD #76612

Other mouse knockout lines are resistant to high-fat-diet-induced weight gain, but in most cases, in contrast to *Fmo5*, the gene disrupted encodes a protein with a known role in fat metabolism or its regulation, for example, protein-tyrosine phosphatase 1B (Klaman *et al.*, 2000), acetyl-CoA carboxylase 2 (Abu-Elheiga *et al.*, 2012) and cidea (Zhou *et al.*, 2003). However, one example in which the product of the disrupted gene is not involved in fat metabolism or its regulation is that of RELM $\beta$  (Hildebrandt *et al.*, 2009).

Although the composition of the gut microbiota of *Fmo5*<sup>-/-</sup> mice changed with age and, in particular, in response to a high-fat diet to that associated with an obesogenic state, these changes had no effect on the metabolic phenotype of the mice. Disruption of a single gene, *Fmo5*, had a similar effect on plasma glucose, plasma insulin and glucose tolerance as did antibiotic-mediated removal of gut microbiota from WT mice. Indeed, *Fmo5*<sup>-/-</sup> mice display metabolic characteristics associated with mice raised in the absence of microorganisms, that is, germ-free, which, in comparison with conventionally reared mice, weigh less, store less fat, have lower plasma glucose and insulin and greater insulin sensitivity and glucose tolerance (Backhed *et al.*, 2007; Rabot *et al.*, 2010). The similarities with germ-free mice suggest that in *Fmo5*<sup>-/-</sup> mice gut flora are ‘invisible’ to the host and that FMO5 has a role in sensing or responding to gut bacteria.

Consistent with the proposed involvement of FMO5 in mediating host response to gut flora is our finding that the protein is expressed in the epithelial lining of the gastrointestinal tract. The concentration of FMO5 at the periphery of secretory granules within goblet cells of the colon and the increase in the abundance of the protein as the cells matured suggests a possible role for FMO5 in events associated with release or processing of granular components. One such component is RELM $\beta$ . *Fmo5*<sup>-/-</sup> mice share some characteristics of a

DMD #76612

RELM $\beta$ -knockout mouse (Hildebrandt *et al.*, 2009): both are protected from diet-induced obesity and protection is independent of diet-induced changes in intestinal microbiota. In addition, the expression of RELM $\beta$ , which is confined to the colon (He *et al.*, 2003), is induced in response to a high-fat diet (Hildebrandt *et al.*, 2009), as was the case for intestinal FMO5 (Fig. 2D).

Our results indicate that absence of FMO5 does not affect expression of RELM $\beta$ , but may affect production in the colon of the monomeric form of the hormone. Studies of resistin, which is closely related to RELM $\beta$ , indicate that the monomer is the active form of the hormone (Patel *et al.*, 2004). If this is the case for RELM $\beta$ , our results indicate that FMO5 may facilitate production of the active monomeric form of the hormone in the colon. Given the phenotypic similarities between *Fmo5*<sup>-/-</sup> and *RELM $\beta$* <sup>-/-</sup> mice, it is possible that these result, in part, from altered production of the RELM $\beta$  monomer in the *Fmo5*<sup>-/-</sup> mice.

Reduction in the plasma concentration of the inflammatory cytokine TNF $\alpha$  as a consequence of disruption of the *Fmo5* gene indicates that FMO5 has a deleterious effect on systemic inflammatory tone. RELM $\beta$  has been identified as a promoter of TNF $\alpha$  synthesis and release from macrophages (McVay *et al.*, 2006). Consequently, the effect of FMO5 on inflammatory tone might be mediated by its influence on production of monomeric RELM $\beta$ .

In addition to its effects on inflammation, TNF $\alpha$  has detrimental effects on insulin sensitivity (Kwon and Pessin, 2013) and a TNF $\alpha$ -knockout mouse is protected against obesity-induced glucose intolerance and hyperinsulinemia (Uysal *et al.*, 1997). Thus, our data suggest that the

## DMD #76612

enhanced whole-body insulin sensitivity of *Fmo5*<sup>-/-</sup> mice results, in part, from reduced expression of TNFα. The lower amount of C3 in epididymal WAT of *Fmo5*<sup>-/-</sup> mice is consistent with the lower plasma concentration in these animals of TNFα, which plays a role in regulating the expression of C3 (Cianflone *et al.*, 2003). C3 is associated with the development of inflammatory-linked metabolic disorders and reduces insulin function (Engström *et al.*, 2005; Samaras *et al.*, 2009; Hertle *et al.*, 2014). Our findings suggest that reduced expression of C3 in WAT, a consequence of reduced circulating TNFα, would contribute to the enhanced whole-body insulin sensitivity of *Fmo5*<sup>-/-</sup> mice. The proposed indirect effect on WAT of disruption of the *Fmo5* gene is consistent with the lack of FMO5 expression in this tissue.

Consistent with its role as a regulator of endogenous metabolic processes, FMO5 displays little genetic variation: within the coding region only two non-synonymous SNPs have been identified, both of which are rare and occur only in individuals of recent African descent (Furnes *et al.*, 2003; Phillips *et al.*, 2007). FMO1, identified as a regulator of energy homeostasis (Veeravalli *et al.*, 2014), also displays little genetic variation (Furnes *et al.*, 2003; Phillips *et al.*, 2007). This is in marked contrast to *FMO2* and *FMO3*, which are highly polymorphic (Phillips *et al.*, 2007).

A SNP (rs7541245) within an intron of the *FMO5* gene has been reported to be marginally significantly associated with a decrease in glycemic response to metformin (Breitenstein *et al.*, 2015). However, it is not known whether metformin can be metabolized by FMO5 and the effect of the SNP on expression or activity of FMO5 has not been established. There is an increasing appreciation of the role of the gut microbiome in metformin response (McCreight

DMD #76612

*et al.*, 2016). Thus, if FMO5 does affect metformin response our data suggest that it may do so via modulation of a host-gut microbiome interaction.

Our results have potential implications for humans. The effect that FMO5 has on the composition of the gut microbiome suggests that interindividual differences in expression of intestinal FMO5 in humans would alter the gut microbiota and, thus, have potential effects on the efficacy of orally administered drugs that are metabolized by gut bacteria.

In addition, our results indicate that interindividual variation in the expression of *FMO5* (Overby *et al.*, 1997) may contribute to differences in weight gain and insulin sensitivity and that induction of FMO5 by some therapeutics (Miller *et al.*, 1997; Rae *et al.*, 2001; Krusekopf and Roots, 2005) may adversely affect the metabolic health of patients. Thus, FMO5 is identified as a potential novel therapeutic target for obesity and insulin resistance. Although the lack of FMO5 apparently promotes a ‘healthy’ metabolic profile, its presence may have conferred an evolutionary advantage, particularly when food supplies were limited, by contributing to the ability of mammals, including humans, to deposit fat and increase weight.

#### **Authorship contributions:**

*Participated in research design:* Scott, O’Brien, Fennema, Phillips, Shephard

*Conducted experiments:* Scott, Gonzalez Malagon, O’Brien, Fennema, Veeravalli, Coveney and Shephard

DMD #76612

*Performed data analysis:* Scott, O'Brien, Fennema, Veeravalli, Phillips, Shephard

*Wrote or contributed to the writing of the manuscript:* Scott, Gonzalez Malagon, O'Brien, Fennema, Veeravalli, Coveney, Phillips and Shephard

## REFERENCES

- Abu-Elheiga L, Wu H, Gu Z, Bressler R, and Wakil SJ (2012) Acetyl-CoA carboxylase 2-/- mutant mice are protected against fatty liver under high-fat, high-carbohydrate dietary and de novo lipogenic conditions. *J Biol Chem* **287**:12578–12588.
- Backhed F, Manchester JK, Semenkovich CF, and Gordon JI (2007) Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. *Proc Natl Acad Sci USA* **104**:979–984.
- Bailey CJ, and Flatt PR (1982) Hormonal control of glucose homeostasis during development and ageing in mice. *Metab Clin Exp* **31**:238–246.
- Breitenstein MK, Wang L, Simon G, Ryu E, Armasu SM, Ray B, Weinshilboum RM, and Pathak J (2015) Leveraging an electronic health record-linked biorepository to generate a metformin pharmacogenomics hypothesis. *AMIA Jt Summits Transl Sci Proc* **2015**:26–30.
- Cianflone K, Xia Z, and Chen LY (2003) Critical review of acylation-stimulating protein physiology in humans and rodents. *Biochim Biophys Acta* **1609**:127–143.
- Daniel H, Moghaddas Gholami A, Berry D, Desmarchelier C, Hahne H, Loh G, Mondot S, Lepage P, Rothballer M, Walker A, Böhm C, Wenning M, Wagner M, Blaut M, Schmitt-Kopplin P, Kuster B, Haller D, and Clavel T (2014) High-fat diet alters gut microbiota physiology in mice. *The ISME Journal* **8**:295–308.
- Dolphin C, Shephard EA, Povey S, Palmer CN, Ziegler DM, Ayesh R, Smith RL, and Phillips IR (1991) Cloning, primary sequence, and chromosomal mapping of a human flavin-containing monooxygenase (FM01). *J Biol Chem* **266**:12379–12385.
- Dolphin CT, Cullingford TE, Shephard EA, Smith RL, and Phillips IR (1996) Differential developmental and tissue-specific regulation of expression of the genes encoding three members of the flavin-containing monooxygenase family of man, FM01, FM03 and FM04. *Eur J Biochem* **235**:683–689.
- Engström G, Hedblad B, Eriksson K-F, Janzon L, and Lindgärde F (2005) Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. *Diabetes* **54**:570–575.
- Fiorentini F, Geier M, Binda C, Winkler M, Faber K, Hall M, and Mattevi A (2016) Biocatalytic characterization of human FM05: unearthing Baeyer-Villiger reactions in humans. *ACS Chem Biol* **11**:1039–1048.

DMD #76612

- Fu ZD, Selwyn FP, Cui JY, and Klaassen CD (2016) RNA sequencing quantification of xenobiotic-processing genes in various sections of the intestine in comparison to the liver of male mice. *Drug Metab Dispos* **44**:842–856.
- Furnes B, Feng J, Sommer SS, and Schlenk D (2003) Identification of novel variants of the flavin-containing monooxygenase gene family in African Americans. *Drug Metab Dispos* **31**:187–193.
- Gonzalez Malagon SG, Melidoni AN, Hernandez D, Omar BA, Houseman L, Veeravalli S, Scott F, Varshavi D, Everett J, Tsuchiya Y, Timms JF, Phillips IR, and Shephard EA (2015) The phenotype of a knockout mouse identifies flavin-containing monooxygenase 5 (FMO5) as a regulator of metabolic ageing. *Biochem Pharmacol* **96**:267–277.
- He W, Wang M-L, Jiang H-Q, Steppan CM, Shin ME, Thurnheer MC, Cebra JJ, Lazar MA, and Wu GD (2003) Bacterial colonization leads to the colonic secretion of RELMbeta/FIZZ2, a novel goblet cell-specific protein. *Gastroenterology* **125**:1388–1397.
- Heikkinen S, Argmann CA, Champy M-F, and Auwerx J (2007) Evaluation of glucose homeostasis. *Curr Protoc Mol Biol* **Chapter 29**:Unit 29B.3–29B.3.22, John Wiley & Sons, Inc., Hoboken, NJ, USA.
- Hernandez D, Janmohamed A, Chandan P, Phillips IR, and Shephard EA (2004) Organization and evolution of the flavin-containing monooxygenase genes of human and mouse: identification of novel gene and pseudogene clusters. *Pharmacogenetics* **14**:117–130.
- Hertle E, Stehouwer CDA, and van Greevenbroek MMJ (2014) The complement system in human cardiometabolic disease. *Molecular immunology* **61**:135–148.
- Hildebrandt MA, Hoffmann C, Sherrill-Mix SA, Keilbaugh SA, Hamady M, Chen Y-Y, Knight R, Ahima RS, Bushman F, and Wu GD (2009) High-fat diet determines the composition of the murine gut microbiome independently of obesity. *Gastroenterology* **137**:1716–24.
- Hogan SP, Seidu L, Blanchard C, Groschwitz K, Mishra A, Karow ML, Ahrens R, Artis D, Murphy AJ, Valenzuela DM, Yancopoulos GD, and Rothenberg ME (2006) Resistin-like molecule beta regulates innate colonic function: barrier integrity and inflammation susceptibility. *J Allergy Clin Immunol* **118**:257–268.
- Hough TA, Nolan PM, Tsipouri V, Toye AA, Gray IC, Goldsworthy M, Moir L, Cox RD, Clements S, Glenister PH, Wood J, Selley RL, Strivens MA, Vizor L, McCormack SL, Peters J, Fisher EM, Spurr N, Rastan S, Martin JE, Brown SDM, and Hunter AJ (2002) Novel phenotypes identified by plasma biochemical screening in the mouse. *Mamm Genome* **13**:595–602.
- Houseman L, Edwards M, Phillips IR, and Shephard EA (2015) Isolation and culture of mouse hepatocytes: gender-specific gene expression responses to chemical treatments, in *Protocols in In Vitro Hepatocyte Research* (Vinken M and Rogiers V eds) *Methods Mol Biol* **1250**:3–12, Springer New York, New York, NY.



DMD #76612

- Hukkanen J, Hakkola J, and Rysä J (2014) Pregnane X receptor (PXR) - a contributor to the diabetes epidemic? *Drug Metabol Drug Interact* **29**:3–15.
- Janmohamed A, Dolphin CT, Phillips IR, and Shephard EA (2001) Quantification and cellular localization of expression in human skin of genes encoding flavin-containing monooxygenases and cytochromes P450. *Biochem Pharmacol* **62**:777–786.
- Janmohamed A, Hernandez D, Phillips IR, and Shephard EA (2004) Cell-, tissue-, sex- and developmental stage-specific expression of mouse flavin-containing monooxygenases (Fmos). *Biochem Pharmacol* **68**:73–83.
- Kaakoush NO (2015) Insights into the role of Erysipelotrichaceae in the human host. *Front Cell Infect Microbiol* **5**:84.
- Klaman LD, Boss O, Peroni OD, Kim JK, Martino JL, Zabolotny JM, Moghal N, Lubkin M, Kim YB, Sharpe AH, Stricker-Krongrad A, Shulman GI, Neel BG, and Kahn BB (2000) Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. *Molecular and cellular biology* **20**:5479–5489.
- Krimi RB, Kotelevets L, Dubuquoy L, Plaisancié P, Walker F, Lehy T, Desreumaux P, Van Seuninghen I, Chastre E, Forgue-Lafitte M-E, and Marie J-C (2008) Resistin-like molecule beta regulates intestinal mucous secretion and curtails TNBS-induced colitis in mice. *Inflamm Bowel Dis* **14**:931–941.
- Krueger SK, and Williams DE (2005) Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. *Pharmacol Ther* **106**:357–387.
- Krusekopf S, and Roots I (2005) St. John's wort and its constituent hyperforin concordantly regulate expression of genes encoding enzymes involved in basic cellular pathways. *Pharmacogenet Genomics* **15**:817–829.
- Kwon H, and Pessin JE (2013) Adipokines mediate inflammation and insulin resistance. *Front Endocrinol* **4**:71.
- Lai WG, Farah N, Moniz GA, and Wong YN (2011) A Baeyer-Villiger oxidation specifically catalyzed by human flavin-containing monooxygenase 5. *Drug Metab Dispos* **39**:61–70.
- Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, and Gordon JI (2005) Obesity alters gut microbial ecology. *Proc Natl Acad Sci USA* **102**:11070–11075.
- Marchesi JR, Sato T, Weightman AJ, Martin TA, Fry JC, Hiom SJ, Dymock D, and Wade WG (1998) Design and evaluation of useful bacterium-specific PCR primers that amplify genes coding for bacterial 16S rRNA. *Appl Environ Microbiol* **64**:795–799.
- McCreight LJ, Bailey CJ, and Pearson ER (2016) Metformin and the gastrointestinal tract. *Diabetologia* **59**:426–435.
- McVay LD, Keilbaugh SA, Wong TMH, Kierstein S, Shin ME, Lehrke M, Lefterova MI,

DMD #76612

- Shifflett DE, Barnes SL, Cominelli F, Cohn SM, Hecht G, Lazar MA, Haczku A, and Wu GD (2006) Absence of bacterially induced RELM $\beta$  reduces injury in the dextran sodium sulfate model of colitis. *The Journal of Clinical Investigation* **116**:2914–2923.
- Mello R de O, Silva CMGD, Fonte FP, Silva DLF, Pereira JA, Margarido NF, and Martinez CAR (2012) Evaluation of the number of goblet cells in crypts of the colonic mucosa with and without fecal transit. *Rev Col Bras Cir* **39**:139–145.
- Meng J, Zhong D, Li L, Yuan Z, Yuan H, Xie C, Zhou J, Li C, Gordeev MF, Liu J, and Chen X (2015) Metabolism of MRX-I, a novel antibacterial oxazolidinone, in humans: the oxidative ring opening of 2,3-Dihydropyridin-4-one catalyzed by non-P450 enzymes. *Drug Metab Dispos* **43**:646–659.
- Miller MM, James RA, Richer JK, Gordon DF, Wood WM, and Horwitz KB (1997) Progesterone regulated expression of flavin-containing monooxygenase 5 by the B-isoform of progesterone receptors: implications for tamoxifen carcinogenicity. *J Clin Endocrinol Metab* **82**:2956–2961.
- Ohmi N, Yoshida H, Endo H, Hasegawa M, Akimoto M, and Higuchi S (2003) S-oxidation of S-methyl-esonarimod by flavin-containing monooxygenases in human liver microsomes. *Xenobiotica* **33**:1221–1231.
- Overby LH, Buckpitt AR, Lawton MP, Attaasafoadjei E, Schulze J, and Philpot RM (1995) Characterization of flavin-containing monooxygenase-5 (FMO5) cloned from human and guinea-pig: evidence that the unique catalytic properties of FMO5 are not confined to the rabbit ortholog. *Arch Biochem Biophys* **317**:275–284.
- Overby LH, Carver GC, and Philpot RM (1997) Quantitation and kinetic properties of hepatic microsomal and recombinant flavin-containing monooxygenases 3 and 5 from humans. *Chem Biol Interact* **106**:29–45.
- Patel SD, Rajala MW, Rossetti L, Scherer PE, and Shapiro L (2004) Disulfide-dependent multimeric assembly of resistin family hormones. *Science* **304**:1154–1158.
- Phillips IR, and Shephard EA (2017) Drug metabolism by flavin-containing monooxygenases of human and mouse. *Expert Opin Drug Metab Toxicol* **13**:167–181.
- Phillips IR, Francois AA, and Shephard EA (2007) The flavin-containing monooxygenases (FMOs): genetic variation and its consequences for the metabolism of therapeutic drugs. *Curr Pharmacogen* **5**:292–313.
- Rabot S, Membrez M, Bruneau A, Gérard P, Harach T, Moser M, Raymond F, Mansourian R, and Chou CJ (2010) Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism. *The FASEB Journal* **24**:4948–4959.
- Rae JM, Johnson MD, Lippman ME, and Flockhart DA (2001) Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. *J Pharmacol Exper Ther* **299**:849–857.
- Salzman NH, de Jong H, Paterson Y, Harmsen HJM, Welling GW, and Bos NA (2002)

DMD #76612

Analysis of 16S libraries of mouse gastrointestinal microflora reveals a large new group of mouse intestinal bacteria. *Microbiology* **148**:3651–3660.

Samaras K, Botelho NK, Chisholm DJ, and Lord RV (2009) Subcutaneous and visceral adipose tissue gene expression of serum adipokines that predict Type 2 diabetes. *Obesity* **18**:884–889.

Siddens LK, Krueger SK, Henderson MC, and Williams DE (2014) Mammalian flavin-containing monooxygenase (FMO) as a source of hydrogen peroxide. *Biochem Pharmacol* **89**:141–147.

Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, Sogin ML, Jones WJ, Roe BA, Affourtit ME, Henrissat B, Heath AC, Knight R, and Gordon JI (2009) A core gut microbiome in obese and lean twins. *Nature* **457**:480–484.

Uysal KT, Wiesbrock SM, Marino MW, and Hotamisligil GS (1997) Protection from obesity-induced insulin resistance in mice lacking TNF- $\alpha$  function. *Nature* **389**:610–614.

Veeravalli S, Omar BA, Houseman L, Hancock M, Gonzalez Malagon SG, Scott F, Janmohamed A, Phillips IR, and Shephard EA (2014) The phenotype of a flavin-containing monooxygenase knockout mouse implicates the drug-metabolizing enzyme FMO1 as a novel regulator of energy balance. *Biochem Pharmacol* **90**:88–95.

Zhang J, and Cashman JR (2006) Quantitative analysis of FMO gene mRNA levels in human tissues. *Drug Metab Dispos* **34**:19–26.

Zhang J, Cerny MA, Lawson M, Mosadeghi R, and Cashman JR (2007) Functional activity of the mouse flavin-containing monooxygenase forms 1, 3, and 5. *J Biochem Mol Toxicol* **21**:206–215.

Zhou Z, Yon Toh S, Chen Z, Guo K, Peng Ng C, Ng CP, Ponniah S, Lin S-C, Hong W, and Li P (2003) Cidea-deficient mice have lean phenotype and are resistant to obesity. *Nat Genet* **35**:49–56.

DMD #76612

### **Footnotes**

This work was supported by the Wellcome Trust [WT093469MA, WT109685MA]; SGGM was funded by a scholarship from CONACYT, Mexico.

## Figure Legends

### **Figure 1: *Fmo5*<sup>-/-</sup> mice are resistant to age-related changes in glucose homeostasis. (A)**

Plasma glucose concentration of WT and *Fmo5*<sup>-/-</sup> (KO) mice with age. 6 weeks: *n* = 4 (WT), *n* = 5 (KO); 8 weeks: *n* = 9 (WT), *n* = 11 (KO); 10 weeks: *n* = 21 (WT), *n* = 24 (KO); 15 weeks: *n* = 18 (WT), *n* = 23 (KO); 20 weeks: *n* = 10 (WT), *n* = 4 (KO); and 30 weeks: *n* = 18 (WT), *n* = 17 (KO). **(B)** Plasma insulin concentration of WT and *Fmo5*<sup>-/-</sup> (KO) mice with age. 10 and 15 weeks (*n* = 4), 30 weeks (*n* = 3). **(C)** GTT of 15-week-old WT and *Fmo5*<sup>-/-</sup> (KO) mice (*n*=6). Insert shows AUC. **(D)** GTT of 30-week-old WT and *Fmo5*<sup>-/-</sup> (KO) mice (*n* = 5). Insert shows AUC. For GTT, mice were starved for 15 h before test. **(E)** Insulin sensitivity test of 10-week-old WT and *Fmo5*<sup>-/-</sup> (KO) mice that had been starved for 6 h (*n* = 4). Insert shows inverse AUC (iAUC). Data are expressed as means ± SEM. \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001.

### **Figure 2: *Fmo5*<sup>-/-</sup> mice are resistant to weight gain and changes in glucose homeostasis in response to a high-fat diet. (A)**

Body weight of WT and *Fmo5*<sup>-/-</sup> (KO) mice fed a high-fat diet (WT, *n* = 7; KO, *n* = 6). **(B)** Plasma insulin concentrations of WT and KO mice fed on standard chow (SC) (*n* = 3) or for six weeks on a high-fat diet (HFD) (WT, *n*=3; KO, *n*=4). **(C)** GTT of WT and KO mice fed on SC (*n* = 5) or a HFD for six weeks (*n* = 4). Insert shows AUC. **(D)** Western blot analysis of fecal proteins from WT mice fed on SC or for six weeks on a HFD. Each lane represents proteins from a different mouse. M, molecular mass standards. The blot was incubated with an antibody against FMO5 and developed as described in Materials and Methods. Protein loading was assessed as described in Materials

DMD #76612

and Methods. **(E)** Western blot analysis of liver proteins from WT mice fed on SC or for six weeks on a HFD. Each lane represents proteins from a different mouse. The blot was incubated with an antibody against FMO5 or actin as the internal loading control. The blot was developed as described in Methods. Data in **A**, **B** and **C** are expressed as means  $\pm$  SEM.  $*P < 0.05$ ,  $**P < 0.01$ ,  $***P < 0.001$ .

**Figure 3: The phenotype of *Fmo5*<sup>-/-</sup> mice is independent of gut microbiota.** Effect of age and diet on gut microbial phyla **(A)** and gut microbial families **(B)** of WT and *Fmo5*<sup>-/-</sup> (KO) mice. SC, mice were fed a standard chow diet; HFD, mice were fed SC then a high-fat diet for six weeks. **(C)** Effect of antibiotic (AB) treatment on plasma concentrations of glucose of 30-week-old mice fed a SC diet. (WT,  $n = 18$ ; WT + AB,  $n = 4$ ; KO,  $n = 17$ ; KO + AB,  $n = 6$ ). **(D)** Effect of antibiotic (AB) treatment on plasma insulin concentration of 30-week-old mice fed a SC diet ( $n = 3$  for each group). **(E)** Effect of antibiotic treatment on glucose tolerance of 30-week-old mice fed a SC diet. +AB, antibiotic treated (WT,  $n = 3$ ; KO,  $n = 5$ ); -AB, untreated ( $n = 5$ ). Insert shows AUC. GTT was done as described in Materials and Methods. Data in **C**, **D** and **E** are expressed as means  $\pm$  SEM.  $*P < 0.05$ ,  $**P < 0.01$ ,  $***P < 0.001$ ,  $****P < 0.0001$ .

**Figure 4: Expression of FMO5 and RELM $\beta$  in mouse intestine. (A)**

Immunohistochemical analysis of sections of stomach and small intestine of 30-week-old mice. Sections were incubated with an antibody against FMO5. Upper panels, WT; lower panels, *Fmo5*<sup>-/-</sup> (KO) mice. Scale bar = 100  $\mu$ m. **(B)** Immunohistochemical analysis of sections of colon of 30-week-old mice. Sections incubated with antibodies against FMO5 (upper panels). Alcian blue staining of sections of colon of 30-week-old mice (lower panels). Left-hand panels, WT; right-hand panels, KO mice. Scale bar = 100  $\mu$ m. **(C)**

## DMD #76612

Immunohistochemical analysis of sections of colon of 30-week-old mice. Sections incubated with antibodies against RELM $\beta$  (upper panels). Lower panel, western blot analysis of colonic content proteins from four WT and three KO mice, d (dimer), m (monomer), MW (molecular weight standards). Protein loading was assessed and the blot was developed as described in Materials and Methods.

**Figure 5: *Fmo5*<sup>-/-</sup> mice have lower amounts of inflammatory markers.** (A) Plasma concentration of TNF $\alpha$  of 30-week-old WT and *Fmo5*<sup>-/-</sup> (KO) mice, either untreated (WT,  $n = 5$ ; KO,  $n = 4$ ) or treated with antibiotics (WT, AB; KO, AB) ( $n = 3$ ). Data are expressed as means  $\pm$  SEM. \* $P < 0.05$ . (B) Western blot analysis of proteins of WAT of 10-week-old WT and KO mice. The blot was incubated with antibodies against C3 or enolase, as a loading control. Blot was developed as described in Materials and Methods.




Figure 1






Figure 2




Figure 3




Figure 4




Figure 5